Peginterferon Alfa-2b Treatment in HBeAg(+) Chronic Hepatitis b Patients Based on Interferon Gene Mutation and Receptor Detection

• Status: Unknown status
• Trial end date: 2018-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The study is to observe the anti-HBV therapeutic effects of peginterferon alfa-2b in chronic hepatitis b patients with e antigen positive based on the detection of interferon gene mutation (IFNA2 p.Ala120Thr) and interferon receptor (IFNAR2) detection.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
• Treatments: Entecavir; Interferon-alpha; Interferons; Peginterferon alfa-2b; Tenofovir

Criteria

Inclusion Criteria:

1. Chronic hepatitis b Patients who should receive anti-HBV therapy according to guideline and are willing to receive interferon therapy;

2. Hepatitis B e antigen positive.

Exclusion Criteria:

1. Patients received anti-HBV therapy in the past 6 months;

2. Patients with liver cirrhosis or hepatocellular carcinoma or other malignancies;

3. Patients with other factors causing active liver diseases;

4. Pregnancy or lactation women;

5. Patients with HIV infection or congenital immune deficiency diseases;

6. Patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications.

7. Patients with other reasons not suitable to receive interferon therapy.